Glycovax Pharma
News
Respiratory diseases—which develop particularly in hospitals, such as those resulting from Pa infections—remain a scourge for which there is currently no effective vaccine. Often resistant to antibiotics, Pa infection is a leading cause of hospital-acquired illness and of infections that are sometimes fatal in people with cystic fibrosis. Glycovax Pharma has optimized manufacturing of the…
Continue readingGlycovax Pharma has been granted a strategic licence by the NRC to develop a semisynthetic vaccine targeting Pseudomonas aeruginosa — a high-priority pathogen according to the WHO, responsible for severe hospital-acquired infections. This vaccine aims to protect vulnerable individuals, especially those living with cystic fibrosis. Continue reading…
Continue readingGlycovax Pharma Inc. is starting the large-scale production of a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). The NRC license has allowed Glycovax to optimize SLA manufacturing by developing a fully synthetic process meeting Good Manufacturing Practices (GMP). Continue reading…
Continue readingPharma Glycovax will participate, from June 16 to 19, 2025, in the BIO International Convention, at the Boston Convention and Exhibition Center, the largest and most comprehensive event for the full ecosystem of biotech with 20,000 industry leaders from across the globe. https://convention.bio.org/bio-2025
Continue reading